India's antitrust watchdog is investigating global fragrance makers Givaudan , Firmenich and International Flavors & Fragrances over accusations of striking anti-poaching deals that can harm workers, ... ...

Core Viewpoint - International Flavors (IFF) has experienced a decline in share price of approximately 14.1% since its last earnings report, underperforming the S&P 500 index [1][2]. Recent Earnings Report - In Q4 2025, IFF reported adjusted earnings of $0.80 per share, missing the Zacks Consensus Estimate of $0.85, and down from $0.93 in the same quarter last year [3]. - The company’s net sales for the quarter were $2.59 billion, a decrease of 6.6% year-over-year, but exceeded the Zacks Consensus Estimate of $2.51 billion [4]. - Currency-neutral sales increased by 1%, driven by mid-single-digit growth in Health & Biosciences and Scent, and low-single-digit growth in Taste [4]. Financial Metrics - Gross profit fell by 9.1% to $891 million, with a gross margin of 34.4%, down from 35.4% in the previous year [5]. - Research and development expenses rose by 2.4% to $174 million, while selling and administrative expenses increased by 12.8% to $383 million [6]. - Adjusted operating EBITDA was $437 million, a decrease of 7.2% from the prior year, with an adjusted operating EBITDA margin of 16.9% [6]. Segment Performance - The Taste segment saw net sales increase by 2.1% to $588 million, with adjusted operating EBITDA rising by 8% to $94 million [7]. - The Food Ingredients segment experienced a decline in net sales by 2.1% to $802 million, but adjusted operating EBITDA increased by 18% to $82 million [7]. - Health & Bioscience segment sales were $586 million, up from $555 million year-over-year, with adjusted operating EBITDA increasing by 14% to $155 million [8]. - The Scent segment's sales rose by 5.5% to $610 million, with adjusted operating EBITDA remaining flat at $106 million [8]. Cash Flow and Balance Sheet - At the end of 2025, IFF had cash and cash equivalents of $590 million, an increase from $469 million at the end of 2024 [9]. - Long-term debt decreased to $4.74 billion from $7.56 billion year-over-year [9]. - Cash generated from operating activities was $0.85 billion, down from $1.07 billion in the previous year [9]. 2025 Performance Overview - For the full year 2025, IFF reported adjusted earnings of $4.20 per share, missing the Zacks Consensus Estimate of $4.28, and down from $4.22 in 2024 [11]. - Total net sales for 2025 were $10.89 billion, a decrease of 5.2% year-over-year, but above the Zacks Consensus Estimate of $10.82 billion [12]. - Currency-neutral sales increased by 2%, attributed to volume growth, productivity gains, and favorable net pricing [12]. 2026 Guidance - IFF expects sales for fiscal 2026 to be between $10.5 billion and $10.8 billion, with adjusted EBITDA projected between $2.05 billion and $2.15 billion [13]. Estimate Trends - There has been a downward trend in estimates, with the consensus estimate decreasing by 7.58% recently [14]. VGM Scores - IFF currently holds a subpar Growth Score of D, a Momentum Score of B, and a Value Score of B, resulting in an aggregate VGM Score of C [15]. Industry Context - IFF operates within the Zacks Chemical - Specialty industry, where competitor Linde (LIN) has seen a 3.7% increase in share price over the past month [17].

Company Overview - International Flavors & Fragrances Inc. (IFF) has a market capitalization of $17.9 billion and operates in the food, beverage, health, biosciences, and fragrance industries through four main segments: Taste, Food Ingredients, Health & Biosciences, and Scent [1] - The company develops flavor solutions for various products, including beverages, dairy, snacks, bakery items, and savory foods, as well as specialty ingredients and natural preservatives [2] Stock Performance - IFF shares have decreased by 17.1% from their 52-week high of $84.45, but have increased by 10.7% over the past three months, outperforming the S&P 500 Index, which declined by 2.3% during the same period [3] - Year-to-date, IFF stock is up 3.9%, while the S&P 500 Index has dropped by 2.5%. However, over the past 52 weeks, IFF shares have declined nearly 12%, lagging behind the S&P 500 Index's return of 19.2% [4] Financial Performance - Following the Q4 2025 results released on February 11, IFF shares rose by 5.9%. In this quarter, adjusted operating EBITDA increased by 7% to $437 million, and adjusted EPS reached $0.80, reflecting productivity gains and cost discipline [5] - The company provided guidance for 2026, projecting sales between $10.5 billion and $10.8 billion, and adjusted operating EBITDA between $2.05 billion and $2.15 billion, alongside strategic actions such as initiating a sale process for the Food Ingredients segment to enhance portfolio focus and financial flexibility [5] Competitive Position - IFF's stock performance has been weaker compared to its rival, Linde plc (LIN), which has returned 15% year-to-date and 8.7% over the past 52 weeks [6]

Core Insights - IFF is expanding its operations in Latin America by establishing a fermentation-based enzyme production hub in Argentina and a household care application laboratory in Brazil, aimed at enhancing its Health & Biosciences business in the region [1] Group 1: Expansion and Innovation - The Arroyito site in Argentina will be transformed into IFF's first full fermentation-based enzyme production hub in Latin America, allowing for local production of high-performance enzymes [1] - The new household care application laboratory in Brazil will enable customers to evaluate and optimize enzyme performance for laundry and dishwashing applications, facilitating faster testing and improved formulation accuracy [1] - IFF's investment in these facilities is expected to improve speed, reliability, and locally relevant solutions for various markets, including brewing, animal nutrition, biofuels, and home care [1] Group 2: Market Growth and Commitment - Latin America is identified as one of the fastest-growing markets for IFF, with a strong emphasis on bioscience-enabled solutions [1] - The company aims to build deeper partnerships with customers and teams across the region to foster sustained innovation and shared growth [1] - IFF's long-term commitment to the region is reinforced by over four decades of industrial biotechnology leadership, positioning the company to capture future growth across multiple sectors [1]

Core Viewpoint - IFF has declared a quarterly cash dividend of $0.40 per share and completed the divestiture of its soy crush, concentrates, and lecithin businesses to Bunge, while also reporting its financial results for the fourth quarter and full year of 2025. Dividend Declaration - IFF's Board of Directors declared a regular quarterly cash dividend of $0.40 per share, payable on April 10, 2026, to shareholders of record as of March 20, 2026 [1]. Divestiture Announcement - IFF successfully completed the divestiture of its soy crush, concentrates, and lecithin businesses to Bunge, excluding the soy isolates business [1]. Financial Results - For the full year 2025, IFF reported consolidated sales of $10.9 billion, a loss before taxes of $412 million, and an earnings per share (EPS) of $(1.46). The operating EBITDA was $2.1 billion with an operating EBITDA margin of 19.2%, and an EPS excluding amortization of $4.20 [1].

Group 1 - International Flavors & Fragrances Inc. (IFF) has seen a significant stock increase of 22% for the year, indicating a potential turnaround after a prolonged period of underperformance [1] - The company operates in three main segments: health and biosciences, scent, and food ingredients, catering to the food, beverage, and personal care industries [3] - Despite the stock's recent performance, there are concerns regarding stagnant sales, with the company experiencing flatlining growth, which is disappointing compared to its historical performance [3]

Financial Performance - In 2025, the company's sales decreased by 5% to $10.890 billion compared to $11.484 billion in 2024, but increased by 2% on a comparable currency neutral basis [191]. - The gross profit for 2025 was $3.938 billion, representing a decrease of $186 million or 5% from $4.124 billion in 2024, with a gross margin of 36.2% [193]. - The operating loss for 2025 was $382 million, compared to an operating profit of $766 million in 2024, marking a significant decline [194]. - Total net sales decreased to $10.890 billion in 2025, down 5.2% from $11.484 billion in 2024, impacted by business divestitures and currency fluctuations [201]. - Segment Adjusted Operating EBITDA decreased by 5% to $2.086 billion in 2025, with a 7% increase on a comparable currency neutral basis [218]. Sales by Segment - The Taste segment reported sales of $2.481 billion in 2025, a 2% increase from $2.428 billion in 2024, with a 4% increase on a comparable currency neutral basis [198]. - The Food Ingredients segment saw a sales decrease of $87 million, or 3%, to $3.278 billion in 2025, with a comparable currency neutral sales decrease of 3% [199]. - Health & Biosciences segment sales increased by $80 million, or 4%, to $2.283 billion in 2025, with a 3% increase on a comparable currency neutral basis [200]. - The Scent segment's sales increased by 2% to $2.479 billion in 2025, with a comparable currency neutral increase of 3% [196]. - Pharma Solutions sales decreased by $680 million, or 65%, to $369 million in 2025, with a 12% increase on a comparable currency neutral basis [203]. Expenses and Costs - Cost of sales decreased by $408 million to $6.952 billion, representing 63.8% of sales in 2025, compared to 64.1% in 2024 [204]. - Research and development (R&D) expenses increased by 3% to $694 million in 2025, representing 6.4% of sales [194]. - S&A expenses decreased by $161 million to $1.834 billion, representing 16.8% of sales in 2025, down from 17.4% in 2024 [206]. - R&D expenses increased by $23 million to $694 million, accounting for 6.4% of sales in 2025, up from 5.8% in 2024 [205]. Impairment Charges - The company recorded an impairment charge of $1.153 billion for the Food Ingredients reporting unit due to goodwill impairment following the segment reorganization [187]. - Impairment of goodwill was $1.153 billion in 2025, significantly higher than $64 million in 2024, related to the Food Ingredients and Pharma Solutions segments [209]. - A goodwill impairment charge of $1.153 billion was recorded for the Food Ingredients reporting unit as of January 1, 2025, leaving no goodwill remaining in that unit [289]. - In 2023, a goodwill impairment charge of $2.623 billion was recorded for the Nourish reporting unit due to its carrying value exceeding fair value [292]. - The company recorded a goodwill impairment charge of $64 million related to the Pharma Solutions disposal group for the year ended December 31, 2024 [291]. Cash Flow and Debt - Cash flows provided by operating activities in 2025 were $850 million, or 7.8% of sales, down from $1.070 billion, or 9.3% of sales, in 2024, primarily due to increased working capital and higher incentive compensation payouts [255]. - Cash flows provided by investing activities surged to $2.269 billion in 2025 from $326 million in 2024, driven by higher net proceeds from business divestitures [257]. - Cash flows used in financing activities increased to $3.091 billion in 2025 from $1.606 billion in 2024, mainly due to the purchase of Senior Notes for $2.0 billion [259]. - As of December 31, 2025, the company had total debt of approximately $6.026 billion, with net debt calculated at $5.436 billion [270]. - The net debt to credit adjusted EBITDA ratio was 2.59 to 1.0 as of December 31, 2025, indicating compliance with financial covenants [268]. Capital Expenditures and Future Outlook - Capital spending in 2026 is expected to be approximately 6% of sales, reflecting a re-prioritization of capital projects [258]. - The company had no outstanding borrowings under its $2 billion Revolving Credit Facility as of December 31, 2025, with available capacity remaining at $2 billion [266]. Tax and Fair Value Considerations - An income tax benefit of $360 million was recognized in 2025 related to the legal entity realignment project, which involved estimating the fair value of relevant legal entities [293]. - The estimated fair value of the Health & Biosciences reporting unit would decrease by 2% if the weighted average cost of capital increased by 50 basis points, potentially resulting in an impairment charge [290]. - The fair value of the company's EUR fixed rate debt was $935 million as of December 31, 2025, with an estimated change of approximately $94 million based on a hypothetical 10% fluctuation in foreign exchange rates [308]. - The fair value of the company's USD fixed rate debt was $4.053 billion as of December 31, 2025, with an estimated change of approximately $405 million based on a hypothetical 10% fluctuation in interest rates [308]. - The estimated fair value of foreign currency forward contracts would change by approximately $199 million based on a hypothetical 10% change in applicable exchange rates [306]. - The company actively monitors foreign currency exposures and employs hedging activities to mitigate the impact of exchange rate fluctuations [304].

Core Viewpoint - International Flavors & Fragrances Inc. (IFF) is recognized as an undervalued chemical stock with positive outlooks from multiple financial institutions, indicating potential for growth and recovery in its performance [1][2]. Financial Performance - IFF reported Q4 net sales of $2.59 billion, reflecting a 7% year-over-year decline but a 1% increase on a currency-neutral basis. Adjusted EPS was $0.80, while GAAP EPS stood at $0.07 [4]. - For the full year 2025, net sales totaled $10.89 billion, down 5% year-over-year but up 2% on a currency-neutral basis. Adjusted operating EBITDA increased by 7%, supported by productivity, volume, and pricing strategies [5]. - The company anticipates 2026 sales between $10.5 billion and $10.8 billion, with adjusted EBITDA projected at $2.05 billion to $2.15 billion, indicating currency-neutral sales growth of 1% to 4% and EBITDA growth of 3% to 8% [5]. Strategic Insights - A shift in strategy towards targeted business investments and organic development, initiated two years ago, is beginning to yield positive results, alleviating concerns regarding the performance of European counterparts [3][9]. - The Health & Biosciences and Scent segments experienced mid-single-digit growth, while the Taste segment saw low-single-digit gains, indicating a diversified growth strategy across different product lines [4]. Market Position - IFF is recognized for creating flavors, fragrances, and cosmetic ingredients for various consumer products, emphasizing innovation and sensory experiences to enhance product offerings [6]. - The company has received positive price target adjustments from major financial institutions, with Deutsche Bank raising its target by $20 and Bank of America increasing it to $100 from $88, maintaining a Buy rating [2].

Core Insights - International Flavors & Fragrances (IFF) has made significant strides in enhancing shareholder value through strategic initiatives [2] - The company has focused on repairing its balance sheet and implementing a disciplined capital allocation strategy, including portfolio optimization via divestitures [2] - A new operating model and key process transformations are being implemented to drive productivity within IFF [2] Company Overview - IFF's products and systems have been adding critical value to consumer companies globally for decades [2] - The leadership team, including CFO Michael DeVeau and CEO Erik Fyrwald, is actively engaged in rejuvenating the company's performance [2]

Summary of International Flavors & Fragrances (IFF) Conference Call Company Overview - **Company**: International Flavors & Fragrances (NYSE:IFF) - **Date**: February 19, 2026 - **Key Speakers**: CFO Michael DeVeau, Yuvraj Arora (Taste Division), Leticia Gonçalves (Health & Biosciences), Ana Paula Mendonça (Scent Division) Core Industry Insights - **Industry**: Flavors and Fragrances - **Market Dynamics**: The industry is characterized by high barriers to entry, steady growth, and good margins. IFF represents 1%-5% of product costs but accounts for 50% of consumer purchasing decisions due to taste and smell [4][5][6]. Financial Performance - **Sales Growth**: IFF achieved $2.5 billion in net sales in 2025 with a 4% organic top-line growth and 10% EBITDA growth [19][28]. - **EBITDA Margins**: The Taste division reported a 19% EBITDA margin, while the Scent division achieved a 21% EBITDA margin [19][41]. - **Capital Structure**: IFF divested 11 businesses, generating $6 billion in proceeds, which improved their capital structure from 4.5 times net cash and credit-adjusted EBITDA in 2023 to 2.6 times [9][13]. Strategic Initiatives - **Portfolio Optimization**: Focus on divesting lower-margin businesses and reinvesting in higher-margin opportunities. The average gross margin of divested businesses was 29%, compared to a projected 36% for the remaining portfolio by 2025 [12][13]. - **Capital Expenditure**: Planned CapEx spending is projected to increase from 4% in 2024 to around 6% in 2026, focusing on capacity expansion and digital transformation [10][11]. - **Share Buyback Program**: IFF authorized a $500 million share buyback program for the first time in several years, indicating confidence in the intrinsic value of the business [14]. Division-Specific Highlights Taste Division - **Market Size**: The flavors market is estimated at $16-$17 billion, growing at 3%-4% annually [18]. - **Competitive Position**: IFF holds leading positions in key markets like India, Indonesia, and the U.S. and has a unique go-to-market model called Taste One for smaller customers [19][20]. - **Innovation Focus**: Emphasis on AI for flavor development and concept creation, reducing innovation timelines for customers [20][21]. Health & Biosciences Division - **Market Size**: The health and biosciences market is valued between $12 billion and $20 billion, growing at 2.5% annually [31]. - **Product Reach**: IFF's probiotics are in one out of three probiotic supplements and yogurts globally, indicating strong market penetration [30]. - **R&D Investment**: IFF invests $220 million annually in R&D, representing 9% of turnover, with 34% of revenue coming from new product launches in the last five years [35]. Scent Division - **Sales Performance**: The Scent division achieved $2.5 billion in sales with 22 consecutive quarters of growth [41][56]. - **Innovation in Fragrance**: IFF has pioneered fragrance encapsulation and is focusing on sustainable solutions and personalization trends driven by younger consumers [44][48]. - **Market Trends**: The division is adapting to clean label demands and the growing role of scent in health and well-being [48][49]. Conclusion - **Growth Strategy**: IFF aims for mid-single-digit top-line growth and high-single-digit EBITDA growth, focusing on innovation, portfolio optimization, and strategic market penetration [28][40][56]. - **Long-term Vision**: The company is committed to leveraging its diversified business model and strong R&D capabilities to drive sustainable growth and value creation [4][28].